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A recent meta-analysis compared the effect of intensive glyce-
mic control vs conventional treatment in type 1 and type 2 DM on
the incidence of macrovascular (cardiac, cerebrovascular, or pe-
ripheral vascular) events.4 This meta-analysis showed that the
combined incidence rate ratios for any macrovascular event with
intensive glycemic control compared with conventional treatment
were 0.38 (95% CI, 0.26-0.56) in type 1 DM and 0.81 (95% CI,
0.73-0.91) in type 2 DM, indicating a substantial risk reduction in
type 1 DM and a smaller risk reduction in type 2 DM.4 These
incidence rate ratios demonstrated that the numbers of patients
who need to receive intensified treatment for 10 years to prevent
onemacrovascular event are 16 for type 1DM, 14 for low-risk type
2 DM, and seven for high-risk type 2 DM.4
Although data from randomized controlled studies are indeed
lacking, the above data2-4 suggest that aggressive control of blood
glucose levels in patients with PAD may improve the risk of
amputation, myocardial infarction, stroke, or vascular death.
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Reply
We would like to thank Dr Paraskevas for his interest in our
article.1 Overall, we agree with his belief that diabetes is an impor-
tant risk factor for peripheral arterial disease (PAD) but chose to
limit the attention paid to it for several reasons. Conceptually, the
vade mecumwas designed to be a specific guide to the treatment of
risk factors for vascular disease and less so for their indications—
more of a “how-to” than a “why” article. As shown by the PAD
Awareness, Risk, and Treatment: New Resources for Survival
(PARTNERS) trial,2 of all risk factors for PAD, primary care
physicians are relatively successful at identifying diabetes and treat-
ing to well-known goals. In contrast to hypertension or hyperlip-
idemia, the additional diagnosis of PAD does not impact on target
goals or choice of pharmacologic agent used in treating it.
Furthermore, although patients with type 2 diabetes, both
with and without PAD, have an increased proclivity for limb loss
and death, no large prospective clinical trial has demonstrated that
intensive blood sugar management has any beneficial effect on
macrovascular outcomes. The United Kingdom Prospective Dia-
betes Study (UKPDS) randomized nearly 4000 newly diagnosed
type 2 diabetic patients to intensive pharmacologic treatment vs
dietary control.3 During 10 years of follow-up, no effect on mac-
rovascular outcomes was observed.
More recently, a large prospective clinical trial arm was halted
for an increased death rate in patients with aggressive blood glu-
cose management. The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was designed to look at the cardiovas-
cular event rates in 10,251 adults with known type 2 diabetes
prospectively randomized to standard treatment to a hemoglobin
A1c goal of 7% to 7.9% vs intensive management with a goal of
6%.4 In response to recommendations from the Data and Safety
Monitoring Board, the study was halted after the finding that
257 patients in the intensive treatment group had died com-
pared with 203 in the standard treatment group after nearly 4
years of follow-up.5
In view of its broad recognition, lack of effect of PAD on
treatment methods or goals, and some controversy regarding the
effect of aggressive glucose management on macrovascular out-
comes, we elected to give diabetes somewhat less attention but no
less consideration. We apologize for any unintentional slight.
Thomas F. Rehring, MD
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